Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
NF-kb (Nuclear factor kappa light chain enhancer of activated B cells) is a family of transcription factors. These are highly conserved factors that control the transcription of DNA, cytokine production, apoptosis, cell growth, and cell survival. It plays a crucial role in regulating responses to infection. It has a role in cellular responses to stimuli such as stress, UV radiation, heavy metals, oxidized LDL, and bacterial and viral antigens. Proper regulation of NF-κB is crucial for the normal functioning of the organs and functions in the body. Incorrect regulation has been linked to various diseases like cancer, inflammatory and autoimmune diseases, septic shock, viral diseases, and improper immune development. Therefore, inhibiting it might be an approach to treating various conditions associated with the pathway. Research is being conducted globally to discover new and novel molecules for anti-IL-23 agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the Department of Health and Human Services, in 2022, the USA had approximately 9.9 per 100,000 people suffering from Amyotrophic Lateral Sclerosis (AML). According to a research study, the incidence of AML in Europe is about 2.2 per 100,000 people in 2022. Therefore, there is an opportunity for the market players globally.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 66 companies have various products in their pipelines, with 51 products in various stages of clinical trials. 7 products are in Phase 4, 12 in Phase 3, 24 in Phase 2, and 8 in Phase 1 of the clinical trials.
Key Developments of NF-κB Inhibitors
Approved Molecules Of Nf-Κb Inhibitors
Drugs In The Pipeline Of Nf-Κb Inhibitors
Clinical Activity and Developments of NF-κB Inhibitors
As of June 2023, 66 companies have approximately 51 products for 243 diseases. For these diseases, 52 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Kremezin (AST-120) |
20 |
|
Fumaderm (dimethyl fumarate) |
14 |
|
Careram (iguratimod) |
9 |
|
Erdotin (erdosteine) |
9 |
|
Kanglaite Injection (KLTi) |
7 |
Drugs like Kremezin (AST-120), Fumaderm (dimethyl fumarate), Careram (iguratimod) etc have been approved by the FDA and other regulatory agencies for the treatment of various indications. Kremezin (AST-120) has been approved for treating Kidney diseases, Chronic Kidney Failure, Chronic Renal Insufficiency, Inflammation, Urologic diseases and others. It is in the clinical trials for various other indications like Digestive system diseases, Acute kidney injury, Crohn’s disease, Fistula, and others. Fumaderm (dimethyl fumarate) is in the clinical trials for various indications like Psoriasis, Papulosquamous skin diseases, Autoimmune and Connective Tissue Diseases, and others. These have shown promising results in clinical trials and have sought approval for various indications by regulatory agencies globally.
Biogen’s Fumaderm (dimethyl fumarate) had a net sale of $4.9 million globally, half-yearly in 2022, compared to sales of $5.9 million in 2021. According to the Department of Health and Human Services, in 2023, 35.5 million people, which equals 14% population, are estimated to have chronic kidney disease (CKD). It is more common in aged people over 65 years of age. It is more common in women (14%) than men (12%). According to a research article, in 2023, the prevalence of CKD in Europe varies according to region, from 3.3% in Norway to 17.3% in Northeast Germany. Therefore, there is an opportunity for the companies in the market to launch their products to fulfil the unmet needs of the population.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Kremezin (AST-120), Fumaderm (dimethyl fumarate), Careram (iguratimod), Erdotin (erdosteine), and Kanglaite Injection (KLTi) are approved by various regulatory agencies.
These are used in treating Chronic Kidney Failure, Chronic Renal Insufficiency, Psoriasis, Papulosquamous skin diseases, Autoimmune and Connective Tissue Diseases, and others.
Reata, Mitsubishi Tanabe, Golden Biotechnology, and Eisai are some of the major market players for NF-?B Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various kinds of cancers are the key opportunities for NF-?B Inhibitors.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
